Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 22;142:109754.
doi: 10.1016/j.mehy.2020.109754. Online ahead of print.

5-Fluorouracil in Combination With Deoxyribonucleosides and Deoxyribose as Possible Therapeutic Options for the Coronavirus, COVID-19 Infection

Affiliations
Free PMC article

5-Fluorouracil in Combination With Deoxyribonucleosides and Deoxyribose as Possible Therapeutic Options for the Coronavirus, COVID-19 Infection

Shamim I Ahmad. Med Hypotheses. .
Free PMC article

Abstract

The recent global pandemic created by the Coronavirus SARS-CoV-2, started in Wuhan, China in December 2019, has generated panic, both in term of human death (4-5% of infected patients identified through testing) and the global economy. Human sufferings seem to be continuing, and it is not clear how long this will continue and how much more destruction it is going to cause until complete control is achieved. One of the most disturbing issues is Covid-19 treatment; although a large number of medications, previously used successfully with other viruses (including Chinese herbal medicines and anti-malaria drugs), are under consideration, there remain questions as to whether they can play a satisfactory role for this disease. Global attempts are ongoing to find the drugs for the treatment of this virus but none of the antiviral drugs used for treatment of other human viral infection is working and hence attempts to find new drugs are continuing. Here the author is proposing that 5-Fluorouracil (5-FU) which when used on its own is failing as an antiviral agent due to the removal of this compound by proof reading ability exceptionally found in Coronaviruses. The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19. Should encouraging results ensue, therapies could then be tried on patients.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

References

    1. J Med Virol. 2020;92(6):540–545. doi: 10.1002/jmv.v92.610.1002/jmv.25733. - DOI
    1. Travel Medicine and Infectious Disease. 2020:101615. doi: 10.1016/j.tmaid.2020.101615. - DOI - PMC - PubMed
    1. Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discov. 2020;14(1):48–60.
    1. BST. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047. - DOI
    1. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrobes Agents Chemother. 2020. Mar 9. Pil:AAC.00399-20.doi:10.1128/AAC.00399-20. [Epub ahead print}.
Feedback